Clinical characteristics and outcomes of patients with angina and heart failure in the CHARM (Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity) Programme
- PMID: 25678097
- DOI: 10.1002/ejhf.221
Clinical characteristics and outcomes of patients with angina and heart failure in the CHARM (Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity) Programme
Abstract
Aims: To investigate the relationship between angina pectoris and fatal and non-fatal clinical outcomes in heart failure with reduced and preserved ejection fraction (HF-REF and HF-PEF, respectively).
Methods and results: Of 7599 patients in the CHARM program, 5408 had ischaemic heart disease; 3855 had HF-REF (ejection fraction ≤45%) and 1553 had HF-PEF. These patients were separated into three groups: no history of angina, previous angina, and current angina. Three coronary outcomes were examined: fatal or non-fatal myocardial infarction (MI); MI or hospitalization for unstable angina (UA); and MI, UA or coronary revascularization. The composite heart failure outcome of cardiovascular death or heart failure hospitalization (HFH) was also analysed, along with its components and all-cause mortality. New York Heart Association functional class was worse in both HF-REF and HF-PEF patients with current angina compared with patients without angina (P < 0.001 and P = 0.005 respectively), despite similar clinical examination findings and ejection fraction. Patients with current angina had a higher risk of all three coronary outcomes (adjusted hazard ratios ranging from 1.8-3.1) than those without angina but did not have a higher risk of heart failure outcomes or all-cause mortality.
Conclusion: In patients with heart failure current angina is associated with significantly more functional limitation and a higher risk of coronary events, across the spectrum of left ventricular ejection fraction.
Keywords: Angina; Heart failure.
© 2015 The Authors. European Journal of Heart Failure © 2015 European Society of Cardiology.
Similar articles
-
International geographic variation in event rates in trials of heart failure with preserved and reduced ejection fraction.Circulation. 2015 Jan 6;131(1):43-53. doi: 10.1161/CIRCULATIONAHA.114.012284. Epub 2014 Nov 18. Circulation. 2015. PMID: 25406306 Clinical Trial.
-
Impact of candesartan on nonfatal myocardial infarction and cardiovascular death in patients with heart failure.JAMA. 2005 Oct 12;294(14):1794-8. doi: 10.1001/jama.294.14.1794. JAMA. 2005. PMID: 16219883
-
Clinical characteristics and outcomes of young and very young adults with heart failure: The CHARM programme (Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity).J Am Coll Cardiol. 2013 Nov 12;62(20):1845-54. doi: 10.1016/j.jacc.2013.05.072. Epub 2013 Jul 10. J Am Coll Cardiol. 2013. PMID: 23850914
-
What have we learned about patients with heart failure and preserved ejection fraction from DIG-PEF, CHARM-preserved, and I-PRESERVE?J Am Coll Cardiol. 2012 Dec 11;60(23):2349-56. doi: 10.1016/j.jacc.2012.04.064. Epub 2012 Nov 7. J Am Coll Cardiol. 2012. PMID: 23141494 Review.
-
Outcomes of heart failure with preserved ejection fraction in a Southeast Asian cohort.J Cardiovasc Med (Hagerstown). 2015 Sep;16(9):583-90. doi: 10.2459/JCM.0000000000000100. J Cardiovasc Med (Hagerstown). 2015. PMID: 25022929 Review.
Cited by
-
Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction.Cochrane Database Syst Rev. 2018 Jun 28;6(6):CD012721. doi: 10.1002/14651858.CD012721.pub2. Cochrane Database Syst Rev. 2018. Update in: Cochrane Database Syst Rev. 2021 May 22;5:CD012721. doi: 10.1002/14651858.CD012721.pub3. PMID: 29952095 Free PMC article. Updated.
-
Potential mechanisms of beneficial effect of sacubitril/valsartan on glycemic control.Ther Adv Endocrinol Metab. 2020 Dec 25;11:2042018820970444. doi: 10.1177/2042018820970444. eCollection 2020. Ther Adv Endocrinol Metab. 2020. PMID: 33489085 Free PMC article. Review.
-
Comparison of Troponin Elevation, Prior Myocardial Infarction, and Chest Pain in Acute Ischemic Heart Failure.CJC Open. 2020 Feb 24;2(3):135-144. doi: 10.1016/j.cjco.2020.02.007. eCollection 2020 May. CJC Open. 2020. PMID: 32462127 Free PMC article.
-
Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction.Cochrane Database Syst Rev. 2021 May 22;5(5):CD012721. doi: 10.1002/14651858.CD012721.pub3. Cochrane Database Syst Rev. 2021. PMID: 34022072 Free PMC article.
-
Effect of sacubitril/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: a post-hoc analysis from the PARADIGM-HF trial.Lancet Diabetes Endocrinol. 2017 May;5(5):333-340. doi: 10.1016/S2213-8587(17)30087-6. Epub 2017 Mar 18. Lancet Diabetes Endocrinol. 2017. PMID: 28330649 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous